Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

Modern Rheumatology

Volumn 20, Issue 6, 2010, Pages 598-601

  Tada, Masahiro ^a   Nakanishi, Takeshi ^a   Hirata, Chika ^a   Okano, Tadashi ^a   Sugioka, Yuko ^a   Wakitani, Shigeyuki ^a   Nakamura, Hiroaki ^a   Koike, Tatsuya ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Infliximab; Pyoderma gangrenosum; Rheumatoid arthritis; Treatment; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; SULFADIAZINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; JOINT SWELLING; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; SEROLOGY; SKIN BIOPSY; SKIN ULCER;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PYODERMA GANGRENOSUM; SKIN; TREATMENT OUTCOME;

EID: 78650509949     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0336-0     Document Type: Article

References (26)

1. JP Callen 1998 Pyoderma gangrenosum Lancet 351 581 585 1:STN:280:DyaK1c7ltlOntw%3D%3D 9492798 10.1016/S0140-6736(97)10187-8 (Pubitemid 28077573)
2. U Wollina 2002 Clinical management of pyoderma gangrenosum Am J Clin Dermatol 3 149 158 11978136 10.2165/00128071-200203030-00002 (Pubitemid 34533775)
3. ML Bennett JM Jackson JL Jorizzo AB Fleischer Jr WL White JP Callen 2000 Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions Medicine (Baltimore) 79 37 46 1:STN:280:DC%2BD3c7jsFejtg%3D%3D 10.1097/00005792-200001000-00004 (Pubitemid 30077735)
4. CN Bernstein JF Blanchard P Rawsthorne N Yu 2001 The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study Am J Gastroenterol 96 1116 1122 1:STN:280:DC%2BD3MzntVWguw%3D%3D 11316157 10.1111/j.1572-0241.2001.03756.x (Pubitemid 32319146)
5. P von den Driesch 1997 Pyoderma gangrenosum: a report of 44 cases with follow-up Br J Dermatol 137 1000 1005 9470924 10.1111/j.1365-2133.1997.tb01568.x (Pubitemid 28011148)
6. S Friedman JF Marion E Scherl PH Rubin DH Present 2001 Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease Inflamm Bowel Dis 7 1 7 1:CAS:528:DC%2BD3MXosVWms74%3D 11233655 10.1097/00054725-200102000-00001
7. J Wenzel R Gerdsen W Phillipp-Dormston T Bieber M Uerlich 2002 Topical treatment of pyoderma gangrenosum Dermatology 205 221 223 1:CAS:528: DC%2BD38Xot1Smsb4%3D 12399665 10.1159/000065843 (Pubitemid 36158528)
8. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand, et al. 1999 Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1398 1405 1:CAS:528:DyaK1MXjtF2mu74%3D 10228190 10.1056/NEJM199905063401804 (Pubitemid 29205403)
9. SR Targan SB Hanauer SJ van Deventer L Mayer DH Present T Braakman, et al. 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1029 1035 1:CAS:528:DyaK2sXmvVKjsrs%3D 9321530 10.1056/NEJM199710093371502 (Pubitemid 27430520)
10. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden, et al. 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 1594 1602 1:CAS:528: DC%2BD3cXovVeltLk%3D 11096166 10.1056/NEJM200011303432202 (Pubitemid 32162982)
11. T Ljung M Staun O Grove O Fausa MH Vatn PM Hellstrom 2002 Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab Scand J Gastroenterol 37 1108 1110 1:STN:280:DC%2BD38nhs1yksw%3D%3D 12374238 10.1080/003655202320378338
12. MH Tan M Gordon O Lebwohl J George MG Lebwohl 2001 Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody Arch Dermatol 137 930 933 1:STN:280:DC%2BD3MvitlyrsA%3D%3D 11453813 (Pubitemid 32641653)
13. F Grange F Djilali-Bouzina AM Weiss A Polette JC Guillaume 2002 Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab Dermatology 205 278 280 1:CAS:528: DC%2BD38Xot1Smsbg%3D 12399677 10.1159/000065860 (Pubitemid 36158539)
14. I Ferkolj A Hocevar R Golouh M Dolenc Voljc 2006 Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease Acta Dermatovenerol Alp Panonica Adriat 15 173 177 17982610 (Pubitemid 46089247)
15. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 1:STN:280:DyaL1c7pt1Ohsg%3D%3D 3358796 10.1002/art.1780310302
16. ML Prevoo MA van 't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44 48 1:STN:280: DyaK2M7hvVeqtA%3D%3D 7818570 10.1002/art.1780380107
17. AM van Gestel ML Prevoo MA van 't Hof MH van Rijswijk LB van de Putte PL van Riel 1996 Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria Arthritis Rheum 39 34 40 8546736 10.1002/art.1780390105 (Pubitemid 26036375)
18. RM Bhat 2004 Management of pyoderma gangrenosum-an update Indian J Dermatol Venereol Leprol 70 329 335 17642657
19. JW McGowan CA Johnson A Lynn 2004 Treatment of pyoderma gangrenosum with etanercept J Drugs Dermatol 3 441 444 15303791
20. M Regueiro J Valentine S Plevy MR Fleisher GR Lichtenstein 2003 Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease Am J Gastroenterol 98 1821 1826 1:CAS:528:DC%2BD3sXlvFGkurk%3D 12907338 10.1111/j.1572-0241.2003.07581.x (Pubitemid 36959164)
21. TN Brooklyn MG Dunnill A Shetty JJ Bowden JD Williams CE Griffiths, et al. 2006 Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial Gut 55 505 509 1:CAS:528: DC%2BD28XjslWls7o%3D 16188920 10.1136/gut.2005.074815
22. Y Tanaka T Takeuchi E Inoue K Saito N Sekiguchi E Sato, et al. 2008 Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) Mod Rheumatol 18 146 152 1:CAS:528: DC%2BD1cXkt1Sksbo%3D 18283523 10.1007/s10165-008-0026-3
23. T Takeuchi H Yamanaka E Inoue H Nagasawa M Nawata K Ikari, et al. 2008 Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) Mod Rheumatol 18 447 454 1:CAS:528:DC%2BD1cXht1anu7rE 18493716 10.1007/s10165-008-0077-5
24. H Nagasawa H Kameda N Sekiguchi K Amano T Takeuchi 2009 Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction Mod Rheumatol 19 166 172 1:CAS:528:DC%2BD1MXjvFaqtLg%3D 19083077 10.1007/s10165-008-0142-0
25. K Fujikawa A Kawakami T Hayashi N Iwamoto SY Kawashiri T Aramaki, et al. 2010 Cutaneous vasculitis induced by TNF inhibitors: a report of three cases Mod Rheumatol 20 86 89 19812889 10.1007/s10165-009-0232-7
26. K Vandevyvere FP Luyten P Verschueren R Lories S Segaert R Westhovens 2007 Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis Clin Rheumatol 26 2205 2206 1:STN:280:DC%2BD2snmsFKjtA%3D%3D 17876646 10.1007/s10067-007-0733-8 (Pubitemid 350120373)